title: What explains the diffusion of treatments for mental illness?
authors.affiliation: Psychiatric Research Center, Lebanon, NH 03766, USA. robert.e.drake@dartmouth.edu
authors.forename: Robert
authors.initials: R
authors.lastname: Drake
authors.forename: Jonathan
authors.initials: J
authors.lastname: Skinner
authors.forename: Howard H
authors.initials: HH
authors.lastname: Goldman
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis / Q000639:trends; D004059:Diffusion of Innovation; D016527:Drug Costs / Q000639:trends; D019317:Evidence-Based Medicine / Q000191:economics; D005544:Forecasting; D006291:Health Policy / Q000191:economics / Q000639:trends; D006801:Humans; D019458:Insurance Coverage / Q000191:economics; D008389:Marketing of Health Services / Q000191:economics; D008484:Medicaid / Q000191:economics; D001523:Mental Disorders / Q000175:diagnosis / Q000191:economics / Q000523:psychology / Q000628:therapy*; D011287:Prejudice; D011785:Quality Assurance, Health Care / Q000191:economics; D012106:Research; D012559:Schizophrenia / Q000188:drug therapy / Q000191:economics; D014481:United States
chemical_list: D014150:Antipsychotic Agents